videothumbnail The ENHERTU View
Watch: The ENHERTU View videothumbnail
Listen to medical experts discuss the efficacy and safety of ENHERTU from DESTINY-Breast 01, including their experience treating these patients with ENHERTU.


Management of thrombocytopenia with ENHERTU1

Thrombocytopenia can occur in patients treated with ENHERTU.1

  • Of the 184 patients with unresectable or metastatic HER2+ breast cancer who received ENHERTU 5.4 mg/kg in DESTINY-Breast01, the incidence of platelet count decrease2
    • Grade 1 incidence 9.8%; Grade 2 incidence 4.3%; Grade 3 incidence 3.3%
  • Based on the severity of thrombocytopenia, manage through treatment interruption or dose reduction1

Dose modifications for thrombocytopenia1

Severity Treatment Modification
Grade 3
(platelets less than 50 to 25 x 109/L)
  • Interrupt ENHERTU until resolved to Grade 1 or less, then maintain dose
Grade 4
(platelets less than 25 x 109/L)

Toxicity grades are in accordance with the National Cancer Institute—Common Terminology Criteria for Adverse Events Version 4.03 (NCI-CTCAE v.4.03).

Get ENHERTU Resources for You and Your Practice

Download icon
ENHERTU Dosage & Administration and Recommendations for Adverse Reactions Guide
Email icon
Ready to learn more about ENHERTU?
HER2, human epidermal growth factor receptor 2.